Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to CAR-T in Large B-cell Lymphoma
NCT06788964Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Utah. Started Aug 2025; status: recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06788964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788964.